A Phase II study of capecitabine plus cisplatin (plustrastuzumab) for previously untreated advanced gastric cancer.

A Phase II study of capecitabine plus cisplatin (plustrastuzumab) for previously untreated advanced gastric cancer. - A Phase II study of capecitabine plus cisplatin (plustrastuzumab) for previously untreated advanced gastric cancer.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006458

Enrollment

Registered

2011-10-03

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

untreated advanced gastric cancer

Interventions

not

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Gastric cancer histologically ptoven adenocarcinoma included egjcancer 2)Presence of a measurable lesion for evaluation according to RECIST1.1 3)Without previous medication history such as radiation therapy chemotherapy and immunotherapy 4)Presence of HER2 5)LVEF more than50% 6)ECOG performance status of 0-2 7)Wrtten informed conscent to recieve this chemotherapy 8)More than 20 years old 9)Adequate organ function as follows 1,Neutrphilcountmorethan 1500mm3 2,Plateletcountmorethan 100000mm3 3,Hemoglobrin more than 9.0g/dl 4,AST,ALTwithin2.5thenormalupperlimits 5,ALP,ALTwithin2.5thenormalupperlimits 6,Serumbilirubinwithin1.5thenormalupperlimits 7,CCRmorethan60mL/min

Exclusion criteria

Exclusion criteria: 1)Severe hypersensitivity to have a history fluorouracil,platinum,trastuzumab 2)Senere renal failure 3)Within seven days stop S-1(tegaful gimerasil oterasil)treatment 4)Intend to make pregnant 5)Others

Design outcomes

Primary

Measure	Time frame
ORR:Overall ResponseRate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026